NovoCure Limited - Ordinary Shares (NVCR): Price and Financial Metrics
NovoCure Limited - Ordinary Shares (NVCR)
Today's Latest Price: $115.89 USD
Updated Oct 28 9:57am
Add NVCR to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
NVCR Stock Summary
- With a price/earnings ratio of 1,041.16, NovoCure Ltd P/E ratio is greater than that of about 99.16% of stocks in our set with positive earnings.
- Price to trailing twelve month operating cash flow for NVCR is currently 335.89, higher than 98.95% of US stocks with positive operating cash flow.
- NVCR's price/sales ratio is 30.03; that's higher than the P/S ratio of 94.09% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to NovoCure Ltd are FLGT, QLYS, SEDG, MOMO, and RNG.
- To check out NovoCure Ltd's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001645113.
NVCR Stock Price Chart Interactive Chart >
NVCR Price/Volume Stats
| Current price | $115.89 | 52-week high | $140.89 |
| Prev. close | $119.50 | 52-week low | $53.40 |
| Day low | $114.28 | Volume | 114,000 |
| Day high | $118.04 | Avg. volume | 996,970 |
| 50-day MA | $106.26 | Dividend yield | N/A |
| 200-day MA | $79.89 | Market Cap | 11.72B |
NovoCure Limited - Ordinary Shares (NVCR) Company Bio
NovoCure Limited is a commercial stage oncology company which develops treatment for solid tumor cancers therapy called the tumor treating fields. The company was founded in 2000 and is based in Saint Helier, Channel Islands.
NVCR Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $115.89 | $1259.21 | 936% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for NovoCure Ltd. To summarize, we found that NovoCure Ltd ranked in the 85th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 941.5%. In terms of the factors that were most noteworthy in this DCF analysis for NVCR, they are:
- The business' balance sheet suggests that 1% of the company's capital is sourced from debt; this is greater than merely 6.15% of the free cash flow producing stocks we're observing.
- As a business, NovoCure Ltd experienced a tax rate of about 211% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 98.16% of stocks generating free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 916% |
| 1% | 926% |
| 2% | 936% |
| 3% | 947% |
| 4% | 957% |
| 5% | 967% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as NVCR, try ARGX, HCA, NHC, FVE, and VMD.
Loading social stream, please wait...